BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAK7. A total of 46 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,840,075 | -2.6% | 10,890,000 | -0.6% | 0.93% | -0.5% |
| Q2 2023 | $11,124,717 | +36.5% | 10,960,000 | +39.8% | 0.93% | +31.1% |
| Q1 2023 | $8,152,676 | -5.8% | 7,840,000 | -1.5% | 0.71% | -9.8% |
| Q4 2022 | $8,654,409 | +3.8% | 7,960,000 | -4.1% | 0.79% | -0.3% |
| Q2 2022 | $8,336,000 | – | 8,300,000 | – | 0.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ADVENT CAPITAL MANAGEMENT /DE/ | 70,652,000 | $71,212,000 | 1.38% |
| SHENKMAN CAPITAL MANAGEMENT INC | 14,821,000 | $14,947,000 | 1.36% |
| AQR Arbitrage LLC | 21,650,000 | $21,800,000 | 0.61% |
| Worth Venture Partners, LLC | 708,000 | $714,000 | 0.27% |
| LOOMIS SAYLES & CO L P | 2,366,716 | $197,478,000 | 0.24% |
| MACKAY SHIELDS LLC | 24,500,000 | $24,670,000 | 0.23% |
| CAMDEN ASSET MANAGEMENT L P /CA | 2,500,000 | $2,505,000 | 0.10% |
| PALISADE CAPITAL MANAGEMENT, LP | 2,429,000 | $2,442,000 | 0.06% |
| Alberta Investment Management Corp | 5,500,000 | $5,545,000 | 0.05% |
| EDMOND DE ROTHSCHILD HOLDING S.A. | 1,900,000 | $1,913,000 | 0.04% |